Triple Negative Breast Cancer research hub
4 indexed studies · 3 currently recruiting
- recruitingPHASE1
PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer
This study looks at combining two drugs, palbociclib and avelumab, for a specific type of advanced breast cancer called triple negative. We want to find the safest dose and see how well it works, especially for cancers with a particular marker called AR.
United Kingdom - recruiting
Breast Cancer Evolution During Neoadjuvant Systemic Therapy
This study, called BELIEVE, collects tissue and blood samples from people with breast cancer before surgery. Researchers want to understand why some cancers respond well to treatment and others don't, how to better measure treatment success, and predict if cancer might return. It helps improve future breast cancer care.
United Kingdom - active not recruitingPHASE2
Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression
This study looks at adding a new drug, ipatasertib, to standard treatment for advanced breast cancer that hasn't responded well to initial therapy. It uses a blood test to identify patients who might benefit most from this additional treatment.
United Kingdom - recruitingPHASE2
A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer
This study looks for tiny traces of cancer DNA in the blood to find early signs of breast cancer coming back. If found, it tests if a new treatment combination (Palbociclib and Fulvestrant) works better than standard treatment for ER-positive, HER2-negative breast cancer.
France · United Kingdom